 CHICAGO DUBLIN--BUSINESS WIRE-- GvokeHypoPen--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission EC has approved OgluoTM glucagon injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation i 